NOR-SWITCH was a randomised, double-blind, non-inferiority parallel-group study that compared the effect of switching from Remicade®† to Inflectra/CT-P13* (infliximab) in 481 patients across all indications.§1
Primary endpoints: Disease worsening across all indications at Week 52.
Disease worsening at Week 52#1
Per-protocol set population. Created from Jørgensen KK, et al. 2017.
Stable patients switching to CT-P13* experienced a similar percentage of disease worsening when measured across all indications compared to those remaining on Remicade® therapy.§1
Learn about the safety and clinical evidence supporting the use of Inflectra in patient with rheumatoid arthritis
Read the guidance on optimising treatment with Inflectra and TDM and biomarkers
Find out more
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020